Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Astellas, Pantherna add organ to mRNA tie-up; Rocket launches sale of six figures worth of stock
3 years ago
R&D
News Briefing
Paul Hudson and TrialSpark's mutual desire to speed up development converges in three-year, six-drug goal
3 years ago
Deals
Pharma
KalVista ends a PhII study early after patients suffer severe and life-threatening side effects
3 years ago
R&D
Penny stock player to review all options to try staying afloat after clinical trial fail
3 years ago
R&D
Looking to push CAR-T in solid tumors, Bay Area biotech goes public in SPAC flip — with slight name change
3 years ago
Financing
Deals
After 12 months of digging, Pfizer opts for one of two Voyager capsids for gene therapy
3 years ago
Deals
Cell/Gene Tx
Takeda to pull key hypoparathyroidism drug from the market after years of manufacturing woes
3 years ago
Manufacturing
Tiny Vergent seals modest Series B in pursuit of cancer imaging agent
3 years ago
Financing
R&D
In post-Covid life, Vir looks to stomp out influenza in up to $1B BARDA contract that boosts GSK-allied mAb
3 years ago
Deals
Coronavirus
Bristol Myers inks protein degrader deal via Celgene team's link to seed-stage biotech
3 years ago
Startups
Deals
Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim
3 years ago
R&D
Sanofi licenses a preclinical genetic disease drug from an unknown biotech spun out of the NIH
3 years ago
Deals
Jeff Marrazzo has found a buzzy new biotech cause to champion. And once again, he's all in
3 years ago
People
Bioregnum
A year and a half after Cellarity raised $123M, the Flagship biotech is back — and it's ready to pick out ...
3 years ago
Financing
Startups
Father starts lab after intellectual property issues stymie rare disease drug development
3 years ago
People
Pharma
Can a smartphone app detect Covid? Pfizer throws down $116M to find out
3 years ago
Deals
Pharma
Big Pharma heavyweights seek tweaks to FDA's clinical outcome assessment guidance
3 years ago
Pharma
FDA+
Another warning letter for Lupin as FDA identifies deficiencies at India-based site
3 years ago
FDA+
Another one bites the dust? FDA warns that emerging Omicron subvariant could make Evusheld obsolete
3 years ago
Coronavirus
Insmed plots upcoming med launches built on its first drug lessons and consumer playbook marketing strategies
3 years ago
Pharma
Marketing
Roche hires new diagnostics chief from within, ahead of C-suite shake-up
3 years ago
People
Pharma
FTC chair Lina Khan pledges to use all tools to investigate PBMs
3 years ago
Pharma
Mesoblast sends in improved potency assay, looking to resubmit to FDA on acute graft-versus-host disease drug
3 years ago
R&D
FDA+
Startup's gold nanocrystal ALS drug flops a PhII trial, a reminder of the disease's obstacles despite Amylyx OK
3 years ago
R&D
First page
Previous page
445
446
447
448
449
450
451
Next page
Last page